Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Report Refutes “Unsubstantiated” Nanotech Concerns, Touts Nano-Sunscreen

This article was originally published in The Tan Sheet

Executive Summary

Current evidence suggests nano-sized ingredients in personal care products pose no more risk to human health than macro-sized ingredients, L'Oreal researchers maintain in a study

You may also be interested in...



Physician-Led Nanodermatology Society Endorses Nano-Sunscreens

With the summer months looming, the Nanodermatology Society announces findings from its scientific literature review, maintaining that nanotechnology in sunscreen products poses no serious health risks to consumers – certainly not in proportion to the dangers of unprotected sun exposure.

Physician-Led Nanodermatology Society Endorses Nano-Sunscreens

With the summer months looming, the Nanodermatology Society announces findings from its scientific literature review, maintaining that nanotechnology in sunscreen products poses no serious health risks to consumers – certainly not in proportion to the dangers of unprotected sun exposure.

Physician-Led Nanodermatology Society Endorses Nano-Sunscreens

With the summer months looming, the Nanodermatology Society announces findings from its scientific literature review, maintaining that nanotechnology in sunscreen products poses no serious health risks to consumers – certainly not in proportion to the dangers of unprotected sun exposure.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel